{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:19:12Z","timestamp":1781248752253,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U54HL142019-01"],"award-info":[{"award-number":["1U54HL142019-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007910-23"],"award-info":[{"award-number":["5T32HL007910-23"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P01HL160472-01"],"award-info":[{"award-number":["1P01HL160472-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although more adeno-associated virus AAV-based drugs enter the clinic, vector tissue tropism remains an unresolved challenge that limits its full potential despite that the tissue tropism of naturally occurring AAV serotypes can be altered by genetic engineering capsid vie DNA shuffling, or molecular evolution. To further expand the tropism and thus potential applications of AAV vectors, we utilized an alternative approach that employs chemical modifications to covalently link small molecules to reactive exposed Lysine residues of AAV capsids. We demonstrated that AAV9 capsid modified with <jats:italic>N<\/jats:italic>-ethyl Maleimide (NEM) increased its tropism more towards murine bone marrow (osteoblast lineage<jats:bold>)<\/jats:bold> while decreased transduction of liver tissue compared to the unmodified capsid. In the bone marrow, AAV9-NEM transduced Cd31, Cd34, and Cd90 expressing cells at a higher percentage than unmodified AAV9. Moreover, AAV9-NEM localized strongly in vivo to cells lining the calcified trabecular bone and transduced primary murine osteoblasts in culture, while WT AAV9 transduced undifferentiated bone marrow stromal cells as well as osteoblasts. Our approach could provide a promising platform for expanding clinical AAV development to treat bone pathologies such as cancer and osteoporosis. Thus, chemical engineering the AAV capsid holds great potential for development of future generations of AAV vectors.<\/jats:p>","DOI":"10.1038\/s41598-023-35547-0","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T10:02:39Z","timestamp":1685008959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Chemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism"],"prefix":"10.1038","volume":"13","author":[{"given":"Patrick L.","family":"Mulcrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh K.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Frabutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Chrzanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland W.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"35547_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/d41573-022-00199-8","volume":"22","author":"A Mullard","year":"2022","unstructured":"Mullard, A. FDA approves first haemophilia B gene therapy. Nat. Rev. Drug Discov. 22, 7 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"35547_CR2","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","volume":"30","author":"A Pupo","year":"2022","unstructured":"Pupo, A. et al. AAV vectors: The Rubik\u2019s cube of human gene therapy. Mol. Ther. 30, 3515\u20133541. https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.015 (2022).","journal-title":"Mol. Ther."},{"key":"35547_CR3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073\u20131080. https:\/\/doi.org\/10.1038\/mt.2008.76 (2008).","journal-title":"Mol. Ther."},{"key":"35547_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","volume":"12","author":"H Buning","year":"2019","unstructured":"Buning, H. & Srivastava, A. Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol. Ther. Methods Clin. Dev. 12, 248\u2013265. https:\/\/doi.org\/10.1016\/j.omtm.2019.01.008 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"35547_CR5","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1089\/hum.2021.124","volume":"32","author":"AK Lam","year":"2021","unstructured":"Lam, A. K., Frabutt, D., Li, L. & Xiao, W. Chemical modifications of the capsid for redirecting and improving the efficacy of adeno-associated virus vectors. Hum. Gene Ther. 32, 1433\u20131438. https:\/\/doi.org\/10.1089\/hum.2021.124 (2021).","journal-title":"Hum. Gene Ther."},{"key":"35547_CR6","doi-asserted-by":"publisher","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","volume":"114","author":"LV Tse","year":"2017","unstructured":"Tse, L. V. et al. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc. Natl. Acad. Sci. U.S.A. 114, E4812\u2013E4821. https:\/\/doi.org\/10.1073\/pnas.1704766114 (2017).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"35547_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1128\/JVI.00976-20","volume":"94","author":"LP Havlik","year":"2020","unstructured":"Havlik, L. P. et al. Coevolution of adeno-associated virus capsid antigenicity and tropism through a structure-guided approach. J. Virol. 94, 20. https:\/\/doi.org\/10.1128\/JVI.00976-20 (2020).","journal-title":"J. Virol."},{"key":"35547_CR8","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/mt.2014.139","volume":"22","author":"D Marsic","year":"2014","unstructured":"Marsic, D. et al. Vector design Tour de Force: Integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Mol. Ther. 22, 1900\u20131909. https:\/\/doi.org\/10.1038\/mt.2014.139 (2014).","journal-title":"Mol. Ther."},{"key":"35547_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1039\/c9sc04189c","volume":"11","author":"M M\u00e9vel","year":"2020","unstructured":"M\u00e9vel, M. et al. Chemical modification of the adeno-associated virus capsid to improve gene delivery. Chem. Sci. 11, 1122\u20131131. https:\/\/doi.org\/10.1039\/c9sc04189c (2020).","journal-title":"Chem. Sci."},{"key":"35547_CR10","doi-asserted-by":"publisher","first-page":"071155","DOI":"10.3390\/molecules22071155","volume":"22","author":"T Yao","year":"2017","unstructured":"Yao, T. et al. Site-specific PEGylated adeno-associated viruses with increased serum stability and reduced immunogenicity. Molecules 22, 071155. https:\/\/doi.org\/10.3390\/molecules22071155 (2017).","journal-title":"Molecules"},{"key":"35547_CR11","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1038\/s41467-019-10809-6","volume":"10","author":"YS Yang","year":"2019","unstructured":"Yang, Y. S. et al. Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. Nat. Commun. 10, 2958. https:\/\/doi.org\/10.1038\/s41467-019-10809-6 (2019).","journal-title":"Nat. Commun."},{"key":"35547_CR12","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.omtm.2020.04.010","volume":"17","author":"YS Yang","year":"2020","unstructured":"Yang, Y. S. et al. Bone-targeting AAV-mediated gene silencing in osteoclasts for osteoporosis therapy. Mol. Ther. Methods Clin. Dev. 17, 922\u2013935. https:\/\/doi.org\/10.1016\/j.omtm.2020.04.010 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"35547_CR13","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1038\/s41467-022-33956-9","volume":"13","author":"YS Yang","year":"2022","unstructured":"Yang, Y. S. et al. Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery. Nat. Commun. 13, 6175. https:\/\/doi.org\/10.1038\/s41467-022-33956-9 (2022).","journal-title":"Nat. Commun."},{"key":"35547_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/gt.2015.89","volume":"23","author":"R Sayroo","year":"2016","unstructured":"Sayroo, R. et al. Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18\u201325. https:\/\/doi.org\/10.1038\/gt.2015.89 (2016).","journal-title":"Gene Ther."},{"key":"35547_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.actbio.2019.04.044","volume":"91","author":"S Lee","year":"2019","unstructured":"Lee, S. & Ahn, H. J. Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo. Acta Biomater. 91, 258\u2013269. https:\/\/doi.org\/10.1016\/j.actbio.2019.04.044 (2019).","journal-title":"Acta Biomater."},{"key":"35547_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.omtm.2022.09.008","volume":"27","author":"AK Lam","year":"2022","unstructured":"Lam, A. K. et al. Fast and high-throughput LC-MS characterization, and peptide mapping of engineered AAV capsids using LC-MS\/MS. Mol. Ther. Methods Clin. Dev. 27, 185\u2013194. https:\/\/doi.org\/10.1016\/j.omtm.2022.09.008 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"35547_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/nmeth.4074","volume":"14","author":"DS Bindels","year":"2017","unstructured":"Bindels, D. S. et al. mScarlet: A bright monomeric red fluorescent protein for cellular imaging. Nat. Methods 14, 53\u201356. https:\/\/doi.org\/10.1038\/nmeth.4074 (2017).","journal-title":"Nat. Methods"},{"key":"35547_CR18","doi-asserted-by":"publisher","first-page":"6807904","DOI":"10.1155\/2022\/6807904","volume":"2022","author":"PL Mulcrone","year":"2022","unstructured":"Mulcrone, P. L. et al. Genomic designs of rAAVs contribute to pathological changes in the livers and spleens of mice. Adv. Cell Gene Ther. 2022, 6807904. https:\/\/doi.org\/10.1155\/2022\/6807904 (2022).","journal-title":"Adv. Cell Gene Ther."},{"key":"35547_CR19","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/jbmr.3133","volume":"32","author":"PL Mulcrone","year":"2017","unstructured":"Mulcrone, P. L. et al. Skeletal colonization by breast cancer cells is stimulated by an osteoblast and beta2AR-dependent neo-angiogenic switch. J. Bone Miner. Res. 32, 1442\u20131454. https:\/\/doi.org\/10.1002\/jbmr.3133 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"35547_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.omtm.2020.05.033","volume":"18","author":"C Zou","year":"2020","unstructured":"Zou, C. et al. Experimental variables that affect human hepatocyte AAV transduction in liver chimeric mice. Mol. Ther. Methods Clin. Dev. 18, 189\u2013198. https:\/\/doi.org\/10.1016\/j.omtm.2020.05.033 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"35547_CR21","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/mt.2016.61","volume":"24","author":"K Vercauteren","year":"2016","unstructured":"Vercauteren, K. et al. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042\u20131049. https:\/\/doi.org\/10.1038\/mt.2016.61 (2016).","journal-title":"Mol. Ther."},{"key":"35547_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1128\/JVI.79.1.214-224.2005","volume":"79","author":"H Nakai","year":"2005","unstructured":"Nakai, H. et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol. 79, 214\u2013224. https:\/\/doi.org\/10.1128\/JVI.79.1.214-224.2005 (2005).","journal-title":"J. Virol."},{"key":"35547_CR23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1089\/ten.TEA.2012.0370","volume":"19","author":"MT Chung","year":"2013","unstructured":"Chung, M. T. et al. CD90 (Thy-1)-positive selection enhances osteogenic capacity of human adipose-derived stromal cells. Tissue Eng. A 19, 989\u2013997. https:\/\/doi.org\/10.1089\/ten.TEA.2012.0370 (2013).","journal-title":"Tissue Eng. A"},{"key":"35547_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00441-018-2894-y","volume":"374","author":"K Futrega","year":"2018","unstructured":"Futrega, K. et al. Bone marrow-derived stem\/stromal cells (BMSC) 3D microtissues cultured in BMP-2 supplemented osteogenic induction medium are prone to adipogenesis. Cell Tissue Res. 374, 541\u2013553. https:\/\/doi.org\/10.1007\/s00441-018-2894-y (2018).","journal-title":"Cell Tissue Res."},{"key":"35547_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.stemcr.2019.05.027","volume":"13","author":"T Hu","year":"2019","unstructured":"Hu, T. et al. Bmi1 suppresses adipogenesis in the hematopoietic stem cell niche. Stem Cell Rep. 13, 545\u2013558. https:\/\/doi.org\/10.1016\/j.stemcr.2019.05.027 (2019).","journal-title":"Stem Cell Rep."},{"key":"35547_CR26","doi-asserted-by":"publisher","first-page":"233943","DOI":"10.3390\/cells11233943","volume":"11","author":"RK Srivastava","year":"2022","unstructured":"Srivastava, R. K., Sapra, L. & Mishra, P. K. Osteometabolism: Metabolic alterations in bone pathologies. Cells 11, 233943. https:\/\/doi.org\/10.3390\/cells11233943 (2022).","journal-title":"Cells"},{"key":"35547_CR27","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.cmet.2016.05.004","volume":"23","author":"P Mera","year":"2016","unstructured":"Mera, P. et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 23, 1078\u20131092. https:\/\/doi.org\/10.1016\/j.cmet.2016.05.004 (2016).","journal-title":"Cell Metab."},{"key":"35547_CR28","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","volume":"130","author":"NK Lee","year":"2007","unstructured":"Lee, N. K. et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456\u2013469. https:\/\/doi.org\/10.1016\/j.cell.2007.05.047 (2007).","journal-title":"Cell"},{"key":"35547_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.omtm.2019.07.003","volume":"14","author":"HA Pearce","year":"2019","unstructured":"Pearce, H. A. et al. Site-specific glycation and chemo-enzymatic antibody sortagging for the retargeting of rAAV6 to inflamed endothelium. Mol. Ther. Methods Clin. Dev. 14, 261\u2013269. https:\/\/doi.org\/10.1016\/j.omtm.2019.07.003 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"35547_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1021\/bc100477g","volume":"22","author":"ED Horowitz","year":"2011","unstructured":"Horowitz, E. D., Weinberg, M. S. & Asokan, A. Glycated AAV vectors: Chemical redirection of viral tissue tropism. Bioconjug. Chem. 22, 529\u2013532. https:\/\/doi.org\/10.1021\/bc100477g (2011).","journal-title":"Bioconjug. Chem."},{"key":"35547_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.coviro.2017.06.003","volume":"24","author":"S Pillay","year":"2017","unstructured":"Pillay, S. & Carette, J. E. Host determinants of adeno-associated viral vector entry. Curr. Opin. Virol. 24, 124\u2013131. https:\/\/doi.org\/10.1016\/j.coviro.2017.06.003 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"35547_CR32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","volume":"30","author":"NL Meyer","year":"2022","unstructured":"Meyer, N. L. & Chapman, M. S. Adeno-associated virus (AAV) cell entry: Structural insights. Trends Microbiol. 30, 432\u2013451. https:\/\/doi.org\/10.1016\/j.tim.2021.09.005 (2022).","journal-title":"Trends Microbiol."},{"key":"35547_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/hgtb.2015.115","volume":"26","author":"B Li","year":"2015","unstructured":"Li, B. et al. Site-directed mutagenesis of surface-exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211\u2013220. https:\/\/doi.org\/10.1089\/hgtb.2015.115 (2015).","journal-title":"Hum. Gene Ther. Methods"},{"key":"35547_CR34","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1172\/JCI57367","volume":"121","author":"CL Bell","year":"2011","unstructured":"Bell, C. L. et al. The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J. Clin. Investig. 121, 2427\u20132435. https:\/\/doi.org\/10.1172\/JCI57367 (2011).","journal-title":"J. Clin. Investig."},{"key":"35547_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/mt.2016.49","volume":"24","author":"C Summerford","year":"2016","unstructured":"Summerford, C., Johnson, J. S. & Samulski, R. J. AAVR: A multi-serotype receptor for AAV. Mol. Ther. 24, 663\u2013666. https:\/\/doi.org\/10.1038\/mt.2016.49 (2016).","journal-title":"Mol. Ther."},{"key":"35547_CR36","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1089\/hum.2015.107","volume":"26","author":"ME Nance","year":"2015","unstructured":"Nance, M. E. & Duan, D. Perspective on adeno-associated virus capsid modification for duchenne muscular dystrophy gene therapy. Hum. Gene Ther. 26, 786\u2013800. https:\/\/doi.org\/10.1089\/hum.2015.107 (2015).","journal-title":"Hum. Gene Ther."},{"key":"35547_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","volume":"20","author":"DA Kuzmin","year":"2021","unstructured":"Kuzmin, D. A. et al. The clinical landscape for AAV gene therapies. Nat. Rev. Drug Discov. 20, 173\u2013174. https:\/\/doi.org\/10.1038\/d41573-021-00017-7 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"35547_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","volume":"26","author":"R Pattali","year":"2019","unstructured":"Pattali, R., Mou, Y. & Li, X. J. AAV9 vector: A novel modality in gene therapy for spinal muscular atrophy. Gene Ther. 26, 287\u2013295. https:\/\/doi.org\/10.1038\/s41434-019-0085-4 (2019).","journal-title":"Gene Ther."},{"key":"35547_CR39","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3389\/fimmu.2020.01293","volume":"11","author":"M Biswas","year":"2020","unstructured":"Biswas, M., Palaschak, B., Kumar, S. R. P., Rana, J. & Markusic, D. M. B cell depletion eliminates FVIII memory B cells and enhances AAV8-coF8 immune tolerance induction when combined with rapamycin. Front. Immunol. 11, 1293. https:\/\/doi.org\/10.3389\/fimmu.2020.01293 (2020).","journal-title":"Front. Immunol."},{"key":"35547_CR40","doi-asserted-by":"publisher","first-page":"666666","DOI":"10.3389\/fimmu.2021.666666","volume":"12","author":"HCJ Ertl","year":"2021","unstructured":"Ertl, H. C. J. T cell-mediated immune responses to AAV and AAV vectors. Front. Immunol. 12, 666666. https:\/\/doi.org\/10.3389\/fimmu.2021.666666 (2021).","journal-title":"Front. Immunol."},{"key":"35547_CR41","doi-asserted-by":"publisher","first-page":"103682","DOI":"10.1016\/j.cellimm.2017.07.012","volume":"342","author":"RW Herzog","year":"2019","unstructured":"Herzog, R. W. et al. Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer. Cell Immunol. 342, 103682. https:\/\/doi.org\/10.1016\/j.cellimm.2017.07.012 (2019).","journal-title":"Cell Immunol."},{"key":"35547_CR42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","volume":"17","author":"AT Martino","year":"2020","unstructured":"Martino, A. T. & Markusic, D. M. Immune response mechanisms against AAV vectors in animal models. Mol. Ther. Methods Clin. Dev. 17, 198\u2013208. https:\/\/doi.org\/10.1016\/j.omtm.2019.12.008 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"35547_CR43","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3389\/fimmu.2017.01604","volume":"8","author":"A Sherman","year":"2017","unstructured":"Sherman, A., Biswas, M. & Herzog, R. W. Innovative approaches for immune tolerance to factor VIII in the treatment of hemophilia A. Front. Immunol. 8, 1604. https:\/\/doi.org\/10.3389\/fimmu.2017.01604 (2017).","journal-title":"Front. Immunol."},{"key":"35547_CR44","doi-asserted-by":"publisher","first-page":"20507","DOI":"10.1021\/jacs.2c09484","volume":"144","author":"Z Yuan","year":"2022","unstructured":"Yuan, Z. et al. Mitigating the immunogenicity of AAV-mediated gene therapy with an immunosuppressive phosphoserine-containing zwitterionic peptide. J. Am. Chem. Soc. 144, 20507\u201320513. https:\/\/doi.org\/10.1021\/jacs.2c09484 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"35547_CR45","doi-asserted-by":"publisher","first-page":"e1001363","DOI":"10.1371\/journal.pbio.1001363","volume":"10","author":"JP Campbell","year":"2012","unstructured":"Campbell, J. P. et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol. 10, e1001363. https:\/\/doi.org\/10.1371\/journal.pbio.1001363 (2012).","journal-title":"PLoS Biol."},{"key":"35547_CR46","doi-asserted-by":"publisher","first-page":"17319","DOI":"10.1038\/s41598-020-74352-x","volume":"10","author":"PL Mulcrone","year":"2020","unstructured":"Mulcrone, P. L. et al. Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23. Sci. Rep. 10, 17319. https:\/\/doi.org\/10.1038\/s41598-020-74352-x (2020).","journal-title":"Sci. Rep."},{"key":"35547_CR47","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.18632\/oncotarget.26831","volume":"10","author":"J Delgado-Calle","year":"2019","unstructured":"Delgado-Calle, J. et al. Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts. Oncotarget 10, 2709\u20132721. https:\/\/doi.org\/10.18632\/oncotarget.26831 (2019).","journal-title":"Oncotarget"},{"key":"35547_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1309\/AJCPBUMQJHVXHRD7","volume":"141","author":"DG Hoffmann","year":"2014","unstructured":"Hoffmann, D. G. & Kim, B. H. Limited flow cytometry panels on bone marrow specimens reduce costs and predict negative cytogenetics. Am. J. Clin. Pathol. 141, 94\u2013101. https:\/\/doi.org\/10.1309\/AJCPBUMQJHVXHRD7 (2014).","journal-title":"Am. J. Clin. Pathol."},{"key":"35547_CR49","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/cyto.a.23845","volume":"95","author":"M Eich","year":"2019","unstructured":"Eich, M., Trumpp, A. & Schmitt, S. OMIP-059: Identification of mouse hematopoietic stem and progenitor cells with simultaneous detection of CD45.1\/2 and controllable green fluorescent protein expression by a single staining panel. Cytometry A 95, 1049\u20131052. https:\/\/doi.org\/10.1002\/cyto.a.23845 (2019).","journal-title":"Cytometry A"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35547-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35547-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35547-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T10:09:25Z","timestamp":1685009365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35547-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35547"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35547-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"9 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors AKL and WX have filed a patent regarding the engineered AAV capsids studied in this work. All other authors have no competing\/conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8436"}}